bryet, Author at BrYet

BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

by bryet | Oct 6, 2025 | Press Releases

HOUSTON and SUNSHINE COAST, Queensland (October 6, 2025) — BrYet US, Inc. (“BrYet”), a biotechnology innovator developing a drug with the potential to be a first-in-class medicine for metastatic disease, today announced that it has received an Australian Human...